Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Walden Biosciences

Request full access

Biotechnology company relentlessly focused on developing first-in-class, highly-targeted therapies for individuals living with kidney disease

Cambridge, United StatesFounded 2020Biotech & Life Sciences

About Walden Biosciences

Walden Biosciences is a biotech startup that operates in the healthcare sector, specifically focusing on the treatment of kidney diseases. The company's mission is to transform the treatment landscape of chronic kidney disease (CKD) and acute kidney injury (AKI). CKD is a condition where the kidneys are progressively damaged and fail over time, while AKI is a rapid loss of kidney function in a short period.

The company's target market is vast, with over 850 million people worldwide suffering from some form of kidney disease. In the US alone, there are 37 million patients with CKD. This number is significantly higher than the number of people suffering from cancer, HIV/AIDS, or diabetes.

Walden Biosciences' business model revolves around the development and commercialization of innovative treatments for kidney diseases. The company generates revenue by conducting clinical trials and eventually selling the developed drugs. Recently, they announced the first subject dosed in their first-in-humans Phase 1 Clinical Trial of WAL0921, a drug in development for the treatment of chronic kidney diseases.

The company also hosts virtual events to educate and engage with the public and potential investors about their work and the importance of their mission. The next event, titled "Transforming the Treatment Landscape of Chronic Kidney Disease," is scheduled for November 14, 2023.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2020
Headquarters
Cambridge, United States
Employees
22
Open positions
None listed
Dealroom signal
79.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Oct 2023 $0 — ATEM Capital —
SERIES AOther financing Oct 2020 $51M $204M ARCH Venture Partners · UCB Ventures —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Walden Biosciences website traffic

Latest recorded traffic for Walden Biosciences is 700 monthly website visits, down 18.6% over the last three months. Walden Biosciences's team grew 4.8% over the past year.

Latest monthly visits700 3-month web change-18.6% 1-year team growth+4.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Walden Biosciences in the Cambridge ecosystem

Live from Dealroom

The Walden Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

Other known investors2 additional known investors

  • Harvard University
  • Rush University
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Walden Biosciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Walden Biosciences’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.